Sermorelin / Ipamorelin

A two-component synthetic peptide blend pairing a 29-residue amidated fragment analog with a 5-residue pentapeptide, both characterized in GPCR structural-biology studies.

Molecular Profile

Type
Peptide blend

Components

Sermorelin (GHRH(1-29) amide)

Molecular formula
C149H246N44O42S
Molecular weight
3357.9 g/mol
CAS number
86168-78-7
Sequence
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2

Ipamorelin

Molecular formula
C38H49N9O5
Molecular weight
711.9 g/mol
CAS number
170851-70-4
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2

Mechanism & Target Class

Combines two synthetic peptides with distinct molecular structures. The first component is a 29-residue C-terminally amidated fragment analog corresponding to the N-terminal GRF(1-29) sequence; in structural studies it engages a class B1 (secretin-family) G-protein-coupled receptor, with cryo-EM resolving the peptide contacts across the receptor transmembrane bundle, extracellular loops, and extracellular domain. The second component is a 5-residue pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) incorporating non-standard residues — an N-terminal Aib and D-amino-acid substitutions — that confer conformational constraint and protease resistance; in structural studies it occupies the ligand-binding pocket of a class A G-protein-coupled receptor. Both components have been resolved in receptor–ligand complexes at near-atomic resolution, supplying molecular-level reference structures for each peptide's GPCR engagement.

Storage & Handling

Lyophilized
−20°C (−80°C long-term); powder protected from moisture and light.
Handling
Aliquot to avoid freeze-thaw cycles; protect from light and moisture.

References (22)

  1. Reviews

    1

    Walker RF. (2006). Clin Interv Aging

    DOI: 10.2147/ciia.2006.1.4.307PubMed 18046908

  2. 2

    Holst B, Schwartz TW. (2004). Trends Pharmacol Sci

    DOI: 10.1016/j.tips.2004.01.010PubMed 15058279

  3. 3

    Laviano A, Molfino A, Rianda S, Rossi Fanelli F. (2012). Curr Pharm Des

    DOI: 10.2174/138161212803216906PubMed 22632856

  4. 4

    Cong Z, Liang YL, Zhou Q, et al. (2022). Trends Pharmacol Sci

    DOI: 10.1016/j.tips.2022.01.002PubMed 35078643

  5. 5

    Halmos G, Szabo Z, Dobos N, et al. (2025). Rev Endocr Metab Disord

    DOI: 10.1007/s11154-025-09952-xPubMed 39934495

  6. Clinical

    6

    Beck DE, Sweeney WB, McCarter MD, et al. (2014). Int J Colorectal Dis

    DOI: 10.1007/s00384-014-2030-8PubMed 25331030NCT00672074

  7. 7

    Pastuszak AW, Sigalos JT, Allison A, et al. (2017). Am J Mens Health

    DOI: 10.1177/1557988317718662PubMed 28830317

  8. 8

    Veldhuis JD, Bowers CY. (2009). Am J Physiol Endocrinol Metab

    DOI: 10.1152/ajpendo.91001.2008PubMed 19240251

  9. 9

    Hindmarsh PC, Brain CE, Robinson IC, et al. (1991). Clin Endocrinol (Oxf)

    DOI: 10.1111/j.1365-2265.1991.tb03548.xPubMed 1684314

  10. 10

    Achermann JC, Hindmarsh PC, Robinson IC, et al. (1999). Clin Endocrinol (Oxf)

    DOI: 10.1046/j.1365-2265.1999.00839.xPubMed 10594518

  11. 11

    Corpas E, Harman SM, Piñeyro MA, et al. (1992). J Clin Endocrinol Metab

    DOI: 10.1210/jcem.75.2.1379256PubMed 1379256

  12. 12

    Hataya Y, Akamizu T, Takaya K, et al. (2001). J Clin Endocrinol Metab

    DOI: 10.1210/jcem.86.9.8002PubMed 11549707

  13. 13

    Brain CE, Hindmarsh PC, Brook CG. (1990). Clin Endocrinol (Oxf)

    DOI: 10.1111/j.1365-2265.1990.tb00851.xPubMed 2140733

  14. 14

    Gobburu JV, Agersø H, Jusko WJ, Ynddal L. (1999). Pharm Res

    DOI: 10.1023/A:1018955126402PubMed 10496658

  15. Primary research

    15

    Zhou F, Zhang H, Cong Z, et al. (2020). Nat Commun

    DOI: 10.1038/s41467-020-18945-0PubMed 33060564

  16. 16

    Yang H, Liu F, Chen W, et al. (2021). Nat Commun

    DOI: 10.1038/s41467-021-26735-5PubMed 34873376

  17. 17

    Raun K, Hansen BS, Johansen NL, et al. (1998). Eur J Endocrinol

    DOI: 10.1530/eje.0.1390552PubMed 9849822

  18. 18

    Wilton P, Chardet Y, Danielson K, et al. (1993). Acta Paediatr Suppl

    DOI: 10.1111/j.1651-2227.1993.tb12827.xPubMed 8329825

  19. 19

    Johansen PB, Nowak J, Skjaerbaek C, et al. (1999). Growth Horm IGF Res

    DOI: 10.1054/ghir.1999.9998PubMed 10373343

  20. 20

    Johansen PB, Hansen KT, Andersen JV, Johansen NL. (1998). Xenobiotica

    DOI: 10.1080/004982598238976PubMed 9879640

  21. 21

    Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. (2002). Histol Histopathol

    DOI: 10.14670/HH-17.707PubMed 12168778

  22. 22

    Andersen NB, Malmlöf K, Johansen PB, et al. (2001). Growth Horm IGF Res

    DOI: 10.1054/ghir.2001.0239PubMed 11735244